Overview

* Zynex Q2 2025 revenue falls 55% yr/yr, missing analyst expectations, per LSEG data

* Net loss widens to $20 mln, or $0.66 per share, in Q2 2025

* Co appoints Steven Dyson as new CEO, aims for strategic refocus

Outlook

* Company suspends revenue and profitability guidance due to leadership changes

* New CEO to review forecasting procedures and update investors

* Company expects $40 mln annualized savings to take effect in Q3 and Q4

Result Drivers

* REVENUE DECLINE - Revenue impacted by Tricare payment suspension and changes to shipment and billing procedures

* FDA SUBMISSION - NiCO laser pulse oximeter submitted to FDA, marking a milestone in product development

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $22.30 $27.40

Revenue mln mln (3

Analysts

)

Q2 EPS -$0.66

Q2 Net -$20 mln

Income

Q2 -$8.90

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Zynex Inc ( ZYXI ) is $6.00, about 58.5% above its July 30 closing price of $2.49

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)